HUE053966T2 - Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) - Google Patents
Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1)Info
- Publication number
- HUE053966T2 HUE053966T2 HUE16744626A HUE16744626A HUE053966T2 HU E053966 T2 HUE053966 T2 HU E053966T2 HU E16744626 A HUE16744626 A HU E16744626A HU E16744626 A HUE16744626 A HU E16744626A HU E053966 T2 HUE053966 T2 HU E053966T2
- Authority
- HU
- Hungary
- Prior art keywords
- programmed death
- binds
- antibody
- receptor
- treating cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562192396P | 2015-07-14 | 2015-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053966T2 true HUE053966T2 (hu) | 2021-08-30 |
Family
ID=56551000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16744626A HUE053966T2 (hu) | 2015-07-14 | 2016-07-14 | Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) |
Country Status (16)
Country | Link |
---|---|
US (3) | US10544224B2 (hu) |
EP (2) | EP3322731B1 (hu) |
JP (2) | JP2018522887A (hu) |
KR (1) | KR20180027576A (hu) |
CN (1) | CN107922502A (hu) |
CY (1) | CY1123993T1 (hu) |
DK (1) | DK3322731T3 (hu) |
ES (1) | ES2855798T3 (hu) |
HR (1) | HRP20210399T1 (hu) |
HU (1) | HUE053966T2 (hu) |
LT (1) | LT3322731T (hu) |
PL (1) | PL3322731T3 (hu) |
PT (1) | PT3322731T (hu) |
RS (1) | RS61532B1 (hu) |
SI (1) | SI3322731T1 (hu) |
WO (1) | WO2017011666A1 (hu) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
PT3303394T (pt) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
JP6786529B2 (ja) | 2015-06-29 | 2020-11-18 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Lpt−723と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
SI3322731T1 (sl) | 2015-07-14 | 2021-03-31 | Bristol-Myers Squibb Company | Postopek za zdravljenje raka z uporabo imunskega inhibitorja kontrolne točke; protitelo ki veže programiran receptor smrti (PD-1) ali programiran smrtni ligand 1 (PD-L1) |
US11008391B2 (en) | 2015-08-11 | 2021-05-18 | WuXi Biologics Ireland Limited | Anti-PD-1 antibodies |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
US20200261573A1 (en) * | 2015-12-17 | 2020-08-20 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
AU2017339856A1 (en) * | 2016-10-06 | 2019-05-23 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗pdl1抗体、およびその使用方法 |
US11701433B2 (en) * | 2017-06-05 | 2023-07-18 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
AU2019206599A1 (en) * | 2018-01-12 | 2020-07-30 | Grail, Inc. | Methods for analyzing viral nucleic acid |
CA3090996A1 (en) * | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
EP3801501A4 (en) * | 2018-06-06 | 2022-03-23 | The Regents of the University of California | ESTROGEN RECEPTOR INHIBITORS AND THEIR USES |
US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
BR112021008117A2 (pt) * | 2018-10-31 | 2021-08-31 | Genentech, Inc. | Método e medicamento para tratamento de câncer que não responde ao inibidor de sinalização pd-1/pd-l1 |
WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
US20230054413A1 (en) * | 2019-12-13 | 2023-02-23 | Samsung Bioepis Co., Ltd. | Stable anti-pd1 antibody pharmaceutical formulations |
CN115087461A (zh) * | 2019-12-20 | 2022-09-20 | 默沙东有限责任公司 | 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法 |
KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
KR20240013352A (ko) | 2022-07-22 | 2024-01-30 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EP1151002A4 (en) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | KDR-SPECIFIC ANTIBODIES AND USES THEREOF |
WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
JP4864900B2 (ja) | 2004-11-18 | 2012-02-01 | イムクローン・リミテッド・ライアビリティ・カンパニー | 血管内皮成長因子受容体−iに対する抗体 |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
NZ564243A (en) * | 2005-06-08 | 2011-03-31 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
US9107887B2 (en) | 2011-03-10 | 2015-08-18 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 |
HUE051954T2 (hu) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | ANTI-PD-L1 ellenanyagok és alkalmazásaik |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
HUE035503T2 (hu) | 2012-10-02 | 2018-05-02 | Bristol Myers Squibb Co | Anti-kir antitestek és anti-PD-1 antitestek kombinációja rák kezelésére |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AU2015265859A1 (en) * | 2014-05-29 | 2016-12-15 | Medimmune Limited | Antagonists of PDL-1 and PD-1 for the treatment of HPV-negative cancers |
US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
KR20170052569A (ko) * | 2014-07-18 | 2017-05-12 | 어드박시스, 인크. | 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용 |
WO2016029073A2 (en) | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
TN2017000440A1 (en) * | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
SI3322731T1 (sl) | 2015-07-14 | 2021-03-31 | Bristol-Myers Squibb Company | Postopek za zdravljenje raka z uporabo imunskega inhibitorja kontrolne točke; protitelo ki veže programiran receptor smrti (PD-1) ali programiran smrtni ligand 1 (PD-L1) |
-
2016
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja active Pending
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Application Discontinuation
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en active Active
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en active Application Filing
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 EP EP20214749.2A patent/EP3858859A1/en active Pending
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-08 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL3322731T3 (pl) | 2021-05-31 |
JP2018522887A (ja) | 2018-08-16 |
US20240124592A1 (en) | 2024-04-18 |
KR20180027576A (ko) | 2018-03-14 |
EP3322731A1 (en) | 2018-05-23 |
WO2017011666A1 (en) | 2017-01-19 |
EP3858859A1 (en) | 2021-08-04 |
RS61532B1 (sr) | 2021-04-29 |
DK3322731T3 (da) | 2021-03-08 |
CN107922502A (zh) | 2018-04-17 |
HRP20210399T1 (hr) | 2021-04-30 |
EP3322731B1 (en) | 2021-01-13 |
PT3322731T (pt) | 2021-02-25 |
US10544224B2 (en) | 2020-01-28 |
US20200190198A1 (en) | 2020-06-18 |
CY1123993T1 (el) | 2022-05-27 |
LT3322731T (lt) | 2021-03-25 |
SI3322731T1 (sl) | 2021-03-31 |
ES2855798T3 (es) | 2021-09-24 |
JP2023024973A (ja) | 2023-02-21 |
US20170037132A1 (en) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE053966T2 (hu) | Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) | |
MX2021003685A (es) | Inhibicion dirigida del factor de crecimiento transformador b (tgfb). | |
HK1251474A1 (zh) | 使用抗ox40抗體和pd-1軸結合拮抗劑治療癌症的方法 | |
HK1252272A1 (zh) | 使用抗ox40抗體治療癌症的方法 | |
IL265525A (en) | New monoclonal antibodies against pd-1 | |
IL265179A (en) | Antibodies against pd-1 (cd27) | |
IL262892A (en) | Anti-pd-1 and anti-lag3 antibodies for cancer therapy | |
IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
IL280766A (en) | Antibodies directed against PD-1 | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
IL263178A (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
IL254131A0 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
WO2016100561A3 (en) | Use of immune checkpoint inhibitors in central nervous systems neoplasms | |
EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
EP3352858A4 (en) | ANTIBODIES THAT RELATE TO THE HUMAN FORM OF LIGAND-2 OF PROGRAMMED CELLULAR DEATH PROTEIN 1 (PD-L2), AND USE THEREOF | |
ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
EP3559044A4 (en) | IMMUNOTHERAPY USING ANTIBODIES THAT BINDING PROGRAMMED CELL DEATH 1 (PD-1) | |
EP3546591A4 (en) | METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO TREATMENT WITH A PD-1 IMMUNE CHECKPOINT INHIBITOR | |
IL277429A (en) | Neutralizing monoclonal antibodies with high affinity for PD-L1 and their uses | |
PT3458478T (pt) | Anticorpos anti pd-1 e anti-lag3 para tratamento de cancro |